Company news
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news
Every Enanta Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
August 10, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 7, 2026
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute...
June 23, 2026
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial V...
June 18, 2026
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
May 11, 2026
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society ...
May 4, 2026
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Deve...
April 13, 2026
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Res...
April 7, 2026
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Associatio...
March 30, 2026
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
March 3, 2026
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Disea...
February 10, 2026
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
February 9, 2026
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
January 8, 2026
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
November 17, 2025
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
November 4, 2025
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Developm...
October 20, 2025
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncyt...
October 7, 2025
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to P...
October 2, 2025
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
September 30, 2025
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 30, 2025
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial...
September 29, 2025
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncyti...
September 26, 2025
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mel...
September 3, 2025
Enanta Pharmaceuticals to Participate in September Investor Conferences
August 21, 2025
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
August 20, 2025
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
August 11, 2025
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
August 5, 2025
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
July 15, 2025
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as th...
June 11, 2025
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 27, 2025
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented ...
May 22, 2025
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
May 12, 2025
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
April 8, 2025
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 17, 2025
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
March 12, 2025
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
February 10, 2025
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
December 24, 2024
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment...
December 9, 2024
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial...
December 6, 2024
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
November 25, 2024
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With...
September 26, 2024
Enanta Pharmaceuticals to Participate in Investor Conferences in September
September 3, 2024
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
August 5, 2024
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
May 29, 2024
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
May 7, 2024
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
May 6, 2024
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
April 30, 2024
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024